Adding trotabresib to chemoradiotherapy did not improve progression-free or overall survival and was associated with more dose reductions and interruptions.
|Videos|September 8, 2016
Telephone Delivery of BRCA Genetic Counseling
Author(s)Anita Y. Kinney, PhD, RN
This video explores a study that found telephone-based genetic counseling for women at risk of hereditary breast and ovarian cancers was noninferior to in-person counseling, with no significant adverse effects on long-term outcomes.
Advertisement
A recent study found that use of telephone-based genetic counseling for women at risk of hereditary breast and ovarian cancers was noninferior to in-person counseling, with no significant adverse effects on long-term outcomes.
In this video, lead study author Anita Y. Kinney, PhD, RN, of the University of New Mexico in Albuquerque, discusses the results of the study. Click here to
Advertisement
Related to this article
The ACS now recommends biennial PSA screening for average-risk men aged 50 to 69 years and annual screening from age 45 for Black men.
Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how he manages anemia, hypoxia, and cardiac toxicity with belzutifan plus lenvatinib for renal cell carcinoma.
National registry data show 5-year overall survival in children and adolescents with cancer rose from 60% in 1975 to 90% in 2017.
Model data suggest anthracycline-based chemotherapy may cost breast cancer survivors a median of 9.4 life-years through biological age acceleration.
Advertisement
Advertisement
Trending on CancerNetwork
1
Anthracycline Chemo May Accelerate Biological Aging in Breast Cancer Survivors
2
CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
3
Managing Hypoxia, Anemia, and Cardiac Toxicity With Belzutifan Plus Lenvatinib
4
Survival in Childhood and Adolescent Cancers Improves, but Racial Disparities Persist
5